NASDAQ:MDWD MediWound (MDWD) Stock Price, News & Analysis $19.33 -0.47 (-2.37%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$19.37 +0.04 (+0.21%) As of 07/30/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MediWound Stock (NASDAQ:MDWD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MediWound alerts:Sign Up Key Stats Today's Range$19.31▼$19.8850-Day Range$18.99▼$22.2452-Week Range$14.14▼$22.50Volume37,360 shsAverage Volume53,406 shsMarket Capitalization$208.96 millionP/E RatioN/ADividend YieldN/APrice Target$32.25Consensus RatingBuy Company Overview MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Read More MediWound Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMDWD MarketRank™: MediWound scored higher than 36% of companies evaluated by MarketBeat, and ranked 743rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMediWound has only been the subject of 3 research reports in the past 90 days.Read more about MediWound's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MediWound are expected to grow in the coming year, from ($2.66) to ($2.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MediWound's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.95% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in MediWound has recently decreased by 3.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.95% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in MediWound has recently decreased by 3.00%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment1.35 News SentimentMediWound has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MediWound this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by Institutions46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MediWound's insider trading history. Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address MDWD Stock News HeadlinesHere's What Could Help MediWound (MDWD) Maintain Its Recent Price StrengthJuly 24, 2025 | msn.comMediWound (NASDAQ:MDWD) Downgraded by Wall Street Zen to "Sell"July 21, 2025 | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)MediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the companyJuly 7, 2025 | finance.yahoo.comMediWound Ltd. (MDWD) latest stock news and headlines - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comCompanies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In GrowthJune 2, 2025 | finance.yahoo.comMediWound’s Q1 2025: Strategic Progress Amid Financial ChallengesMay 21, 2025 | tipranks.comMediWound (MDWD) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comSee More Headlines MDWD Stock Analysis - Frequently Asked Questions How have MDWD shares performed this year? MediWound's stock was trading at $17.80 on January 1st, 2025. Since then, MDWD stock has increased by 8.6% and is now trading at $19.33. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) issued its quarterly earnings data on Wednesday, May, 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. The biopharmaceutical company earned $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 110.45% and a negative trailing twelve-month return on equity of 74.12%. Read the conference call transcript. When did MediWound's stock split? Shares of MediWound reverse split on Tuesday, December 20th 2022.The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. Who are MediWound's major shareholders? Top institutional shareholders of MediWound include Silverberg Bernstein Capital Management LLC (1.36%), ARK Investment Management LLC (0.88%) and Janney Montgomery Scott LLC (0.13%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/21/2025Today7/30/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDWD CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees80Year Founded2001Price Target and Rating Average Price Target for MediWound$32.25 High Price Target$39.00 Low Price Target$25.00 Potential Upside/Downside+66.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.22 million Net Margins-110.45% Pretax Margin-110.23% Return on Equity-74.12% Return on Assets-30.92% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio1.99 Sales & Book Value Annual Sales$20.22 million Price / Sales10.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book6.69Miscellaneous Outstanding Shares10,810,000Free Float9,814,000Market Cap$208.96 million OptionableOptionable Beta0.32 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:MDWD) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.